Armistice Capital’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Armistice Capital’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-32,500	Closed	-$1.31M	–	244
2024 Q3	$1.31M	Buy	32,500 +6,557	+25%	+$351K	0.02%	166
2024 Q2	$1.34M	Buy	25,943 +6,803	+36%	+$322K	0.02%	156
2024 Q1	$850K	Buy	19,140 +11,422	+148%	+$477K	0.01%	172
2023 Q4	$340K	Buy	+7,718	New	+$332K	﹤0.01%	216
2023 Q2	–	Sell	-16,500	Closed	-$756K	–	231
2023 Q1	$756K	Buy	+16,500	New	+$1.19M	0.01%	147
2021 Q4	–	Sell	-4,375	Closed	-$1.45M	–	151
2021 Q3	$1.45M	Buy	+4,375	New	+$1.72M	0.02%	121

Other funds holding CANF

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

KBFS

Kohmann Bosshard Financial Services Fairlawn, Ohio $1.18B AUM 16.34% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Armistice Capital's CANF Position: Q4 2024 in Review

Armistice Capital sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q4 2024, closing a stake of 32,500 shares — an estimated $1.31M sold.

Armistice Capital first reported a position in CANF in Q3 2021 and held it in 6 quarters. The position peaked at $1.45M in Q3 2021. 12 funds tracked by Wall St. Rank hold CANF as of Q4 2024.

Armistice Capital reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q4 2024 after selling out during the quarter.
Armistice Capital sold 32,500 Can-Fite BioPharma American Depositary Shares shares in Q4 2024, an estimated $1.31M.
Armistice Capital first reported a position in Can-Fite BioPharma American Depositary Shares in Q3 2021 and held it in 6 quarters.
Armistice Capital's Can-Fite BioPharma American Depositary Shares position peaked at $1.45M in Q3 2021.
12 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.